BRISTOL-MYERS SQUIBB LAUNCHING PRAVACHOL IN MID-NOVEMBER AT 5- 10% DISCOUNT TO MEVACOR; SECOND HMG-COA REDUCTASE INHIBITOR APPROVED BY FDA ON OCT. 31